Hallmark Capital Management Inc. lessened its position in shares of Johnson & Johnson (NYSE:JNJ) by 0.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 119,210 shares of the company’s stock after selling 995 shares during the period. Johnson & Johnson comprises 1.9% of Hallmark Capital Management Inc.’s investment portfolio, making the stock its 17th biggest holding. Hallmark Capital Management Inc.’s holdings in Johnson & Johnson were worth $16,765,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of JNJ. Capital World Investors grew its holdings in Johnson & Johnson by 182.9% during the 1st quarter. Capital World Investors now owns 21,195,989 shares of the company’s stock worth $2,779,435,000 after acquiring an additional 13,703,905 shares in the last quarter. Wellington Management Group LLP grew its holdings in Johnson & Johnson by 10.8% during the 1st quarter. Wellington Management Group LLP now owns 30,556,662 shares of the company’s stock worth $4,006,895,000 after acquiring an additional 2,968,879 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in Johnson & Johnson by 7.7% during the 1st quarter. Massachusetts Financial Services Co. MA now owns 29,526,058 shares of the company’s stock worth $3,871,753,000 after acquiring an additional 2,118,870 shares in the last quarter. Capital International Investors boosted its holdings in shares of Johnson & Johnson by 13.6% in the 1st quarter. Capital International Investors now owns 16,726,965 shares of the company’s stock valued at $2,193,411,000 after buying an additional 2,004,688 shares in the last quarter. Finally, Swiss National Bank boosted its holdings in shares of Johnson & Johnson by 21.9% in the 1st quarter. Swiss National Bank now owns 11,147,766 shares of the company’s stock valued at $1,461,807,000 after buying an additional 2,003,900 shares in the last quarter. Institutional investors own 68.44% of the company’s stock.
Shares of Johnson & Johnson stock opened at $145.76 on Friday. The company has a market cap of $383.76 billion, a P/E ratio of 21.31, a PEG ratio of 3.23 and a beta of 0.69. The company has a debt-to-equity ratio of 0.40, a quick ratio of 1.05 and a current ratio of 1.25. Johnson & Johnson has a one year low of $109.16 and a one year high of $157.00. The firm has a fifty day moving average of $144.04 and a two-hundred day moving average of $144.14.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Thursday, July 16th. The company reported $1.67 EPS for the quarter, topping the Zacks’ consensus estimate of $1.50 by $0.17. The company had revenue of $18.34 billion during the quarter, compared to the consensus estimate of $17.73 billion. Johnson & Johnson had a net margin of 22.69% and a return on equity of 35.21%. Johnson & Johnson’s quarterly revenue was down 10.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.58 EPS. As a group, equities analysts predict that Johnson & Johnson will post 7.85 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be given a dividend of $1.01 per share. The ex-dividend date is Monday, August 24th. This represents a $4.04 dividend on an annualized basis and a yield of 2.77%. Johnson & Johnson’s payout ratio is currently 46.54%.
In other news, EVP Ashley Mcevoy sold 29,000 shares of the company’s stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $147.47, for a total transaction of $4,276,630.00. Following the transaction, the executive vice president now directly owns 21,682 shares of the company’s stock, valued at approximately $3,197,444.54. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.27% of the stock is currently owned by corporate insiders.
Several research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $150.00 target price for the company. in a report on Tuesday, July 7th. Wells Fargo & Co upgraded shares of Johnson & Johnson to a “hold” rating in a report on Wednesday, April 22nd. Credit Suisse Group restated a “buy” rating and issued a $161.00 target price on shares of Johnson & Johnson in a report on Tuesday, April 28th. Barclays upped their target price on shares of Johnson & Johnson from $173.00 to $182.00 and gave the company an “overweight” rating in a report on Wednesday, April 29th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $168.00 target price on shares of Johnson & Johnson in a report on Tuesday, April 28th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. Johnson & Johnson currently has an average rating of “Buy” and an average target price of $163.38.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: Fiduciary
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.